A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
The phase 3, randomized, double-blind registration study sought to assess the safety and efficacy of alternating treatment with EP2006 and the reference filgrastim for the prevention of severe neutropenia in patients undergoing myelosuppressive chemotherapy in the neoadjuvant setting.
The study comprised 218 patients who received the reference filgrastim or its biosimilar together with 6 cycles of chemotherapy. The patients were randomized into 4 arms; 2 arms received only 1 of the treatment products, either the EP2006 or the reference, and did not switch treatments. 2 arms received alternating treatments of the biosimilar and reference product (or vice versa) over cycles 1 to 6. The analysis compared the safety and efficacy of the 2 treatments between the pooled switched groups and the unswitched reference group over cycles 2 to 6. The researchers pre-defined a margin with a 95% confidence interval (CI), to demonstrate non-inferiority of the biosimilar product in febrile neutropenia (FN) rates between the switched an unswitched groups, for treatment cycles 2 to 6.
A total of 107 patients switched treatment, while 51 patients received the reference product in all cycles. Baseline characteristics were similar between the 2 treatment groups. The incidence of FN for the switched group was 3.4%, compared with 0% in the group that received the reference product alone (95% CI, range -9.65 to 4.96), a rate that fell within the pre-defined margin. Only 1 patient (switched group) was hospitalized due to FN. Infections were noted in 9.3% of the switched group versus 9.9% of the reference group. Treatment emergent adverse events were reported in 42.1% of patients in the switched group versus 39.2% of the reference group. Musculoskeletal and connective tissue disorders related to treatment with filgrastim were noted in 35.5% of the switched group versus 39.2% of the reference group. No patients developed anti-drug antibodies during the study period.
The researchers concluded that there was no evidence of clinically meaningful differences when patients undergoing treatment for breast cancer were switched between biosimilar filgrastim and reference filgrastim, or vice versa.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.